Sandoz, the global leader in affordable medicines, announced the launch of Enzeevu (aflibercept) in Canada, its first ophthalmology biosimilar, expanding access to affordable treatment options for people living with serious retinal diseases across Canada. Enzeevu is a biosimilar to the reference medicine EYLEA1 and is approved for all indications of the reference medicine:
- neovascular (wet) age-related macular degeneration (AMD)
- visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO)
- visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO)
- diabetic macular edema (DME)
- myopic choroidal neovascularization (myopic CNV)
These conditions are among the leading causes of vision impairment in Canada, particularly affecting older adults and people living with diabetes.2
Addressing the Growing Need for Affordable Retinal Disease Treatment
‘’With the growing prevalence of retinal diseases, access to effective and affordable treatment options has never been more important. By offering a biosimilar to one of the most widely used therapies in this field, we are helping to improve affordability and access for thousands of patients nationwide.’’ – Michel Robidoux, President and General Manager, Sandoz Canada.
Enzeevu is supplied as a 2 mg/0.05 mL solution for intravitreal injection in a single-use pre-filled syringe, delivering a single dose of 2 mg aflibercept. The product has a similar appearance to the reference medicine, supporting continuity of care and facilitating the transition for patients currently receiving treatment.
Patients and healthcare professionals will also benefit from a comprehensive patient support program during treatment with Enzeevu, providing practical support and guidance throughout the entire patient experience.
This launch reinforces the Sandoz Purpose of pioneering access for patients and reflects the company’s continued commitment to expanding its biosimilars portfolio into new therapeutic areas, including ophthalmology. As a leader in affordable medicines, Sandoz Canada continues to work with healthcare partners to support sustainable healthcare systems and improved patient outcomes.
References
1 EYLEA is a registered trademark of Bayer Inc.
2 Fighting Blindness in Canada. A Report Card on Vision Health in Canada 2023. https://www.fightingblindness.ca/wp-content/uploads/2024/10/Report-Card-Vision-Health_acc.-digital.pdf
